title: Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease.
abstract: Parkinson's disease (PD) is a neurodegenerative disorder with highly heterogeneous clinical manifestations. This fact has prompted many attempts to divide PD patients into clinical subgroups. This could lead to a better recognition of pathogenesis, improving targeted treatment and the prognosis of PD patients. The aim of the present study was to obtain cerebrospinal fluid (CSF) samples in PD patients and to search for a relationship between neurodegenerative CSF markers (tau protein, beta-amyloid(1-42) and index tau protein/beta-amyloid(1-42)) and the clinical subtypes. PD patients were divided into three subgroups: early disease onset (EDO), tremor-dominant PD (TD-PD), and non-tremor dominant PD (NT-PD) according to the previously published classification. Neurodegenerative markers in the CSF were assessed in these three groups of patients suffering from PD (EDO-17, TD-15, NT-16 patients) and in a control group (CG) of 19 patients suffering from non-degenerative neurological diseases and 18 patients with Alzheimer's disease (AD). The NT-PD patients were found to have significantly higher levels of CSF tau protein and index tau/beta than the control subjects and other Parkinsonian subgroups, but no significant differences in these markers were found between AD and NT-PD patients. In the context of more rapid clinical progression and more pronounced neuropathological changes in the NT-PD patient group, our results corroborate the opinion that CSF level of tau protein may be regarded as a potential laboratory marker of the presence and severity of neurodegeneration.
authors: Department of Neurology, Faculty of Medicine and Dentistry, Palacky University in Olomouc, University Hospital Olomouc, I.P. Pavlova 6, 775 20 Olomouc, Czech Republic. vranovaha@seznam.cz
authors: Hana
authors: H
authors: Přikrylová Vranová
authors: Jan
authors: J
authors: Mareš
authors: Petr
authors: P
authors: Hluštík
authors: Martin
authors: M
authors: Nevrlý
authors: David
authors: D
authors: Stejskal
authors: Jana
authors: J
authors: Zapletalová
authors: Radko
authors: R
authors: Obereigneru
authors: Petr
authors: P
authors: Kaňovský
mesh_terms: D000328:Adult; D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000523:psychology; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000134:cerebrospinal fluid* / Q000523:psychology; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D010641:Phenotype; D016875:tau Proteins / Q000134:cerebrospinal fluid*
chemical_list: D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins